Thermo Fisher Scientific CEA Monoclonal Antibody (H.426.3)

Applications and Tested Dilution

Product Specifications

Product Specific Information

It is not recommended to aliquot this antibody.

Target Information

CEA (Carcino Embryonic Antigen, CD66e) is synthesized during development in the fetal gut and re-expressed in increased amounts in intestinal carcinomas and several other tumors.
CEA belongs to the immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable region) and six immunoglobulin constant-like A (A1, A2, A3) and B (B1, B2, B3) domains.

Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60–70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).
CEA is a large family of glycoproteins and serves as a useful tumor marker for adenocarcinoma, found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.

Two subgroups of the CEA family—the CEA cell adhesion molecules and the pregnancy-specific glycoproteins—are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in this cluster.

CEA was originally described in bile ducts of the liver as biliary glycoprotein. Subsequently, it was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic and heterophilic binding to other subgroup proteins.

Multiple cellular activities have been attributed to the encoded protein, including roles in differentiation, tissue structural arrangement, angiogenesis, apoptosis, tumor suppression, metastasis, and modulation of immune responses. Multiple transcript variants encoding different isoforms have been reported, though their full-length nature has not been defined.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.